ObsEva SA (NASDAQ:OBSV – Get Rating) has received an average recommendation of “Buy” from the seven brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $12.33.
OBSV has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of ObsEva in a report on Monday, May 23rd. StockNews.com raised ObsEva from a “sell” rating to a “hold” rating in a research note on Sunday, June 5th. Cantor Fitzgerald assumed coverage on ObsEva in a report on Friday, June 3rd. They issued an “overweight” rating and a $6.00 target price for the company. Canaccord Genuity Group started coverage on ObsEva in a research report on Tuesday, April 26th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, Aegis initiated coverage on ObsEva in a research note on Monday, March 28th. They issued a “buy” rating and a $12.00 target price on the stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. raised its position in shares of ObsEva by 8.3% in the 3rd quarter. Goldman Sachs Group Inc. now owns 91,496 shares of the company’s stock valued at $285,000 after acquiring an additional 7,016 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in ObsEva by 2.7% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 578,126 shares of the company’s stock worth $1,150,000 after acquiring an additional 15,000 shares in the last quarter. Banque Cantonale Vaudoise grew its holdings in ObsEva by 143.2% during the first quarter. Banque Cantonale Vaudoise now owns 28,868 shares of the company’s stock worth $44,000 after purchasing an additional 17,000 shares during the period. Virtu Financial LLC bought a new position in ObsEva during the first quarter worth $30,000. Finally, XTX Topco Ltd raised its holdings in ObsEva by 33.9% in the 1st quarter. XTX Topco Ltd now owns 79,757 shares of the company’s stock valued at $120,000 after acquiring an additional 20,196 shares during the period. Hedge funds and other institutional investors own 27.80% of the company’s stock.
OBSV stock opened at $1.84 on Wednesday. The firm has a 50 day moving average price of $1.63 and a 200-day moving average price of $1.65. The firm has a market capitalization of $143.47 million, a price-to-earnings ratio of -2.88 and a beta of 0.65. ObsEva has a 52-week low of $1.08 and a 52-week high of $3.58. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.09 and a current ratio of 3.09.
About ObsEva (GetRated)
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in ObsEva right now?
Before you consider ObsEva, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and ObsEva wasn’t on the list.
While ObsEva currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here